ATE78827T1 - Topisches arzneimittel enthaltend 17-beta-methoxy-carbonyl-4-methyl-4-aza-5-alpha androst-1-en-3- one. - Google Patents

Topisches arzneimittel enthaltend 17-beta-methoxy-carbonyl-4-methyl-4-aza-5-alpha androst-1-en-3- one.

Info

Publication number: ATE78827T1
Authority: AT; Austria
Prior art keywords: alpha; methyl; androst; aza; methoxy
Prior art date: 1986-11-20

Application number

AT87309949T

Other languages

English (en)

Inventor

Gary H Rasmusson

Glenn F Reynolds

Original Assignee

Merck & Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-11-20

Filing date

1987-11-11

Publication date

1992-08-15

1987-11-11 Application filed by Merck & Co Inc filed Critical Merck & Co Inc

1992-08-15 Application granted granted Critical

1992-08-15 Publication of ATE78827T1 publication Critical patent/ATE78827T1/de

Links

239000003814 drug Substances 0.000 title 1
229940079593 drug Drugs 0.000 title 1
230000000699 topical effect Effects 0.000 title 1
229910052739 hydrogen Inorganic materials 0.000 abstract 2
239000001257 hydrogen Substances 0.000 abstract 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 abstract 1
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 abstract 1
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 abstract 1
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 abstract 1
239000002677 5-alpha reductase inhibitor Substances 0.000 abstract 1
208000002874 Acne Vulgaris Diseases 0.000 abstract 1
206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
206010020112 Hirsutism Diseases 0.000 abstract 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
206010039792 Seborrhoea Diseases 0.000 abstract 1
206010000496 acne Diseases 0.000 abstract 1
125000000217 alkyl group Chemical group 0.000 abstract 1
125000003710 aryl alkyl group Chemical group 0.000 abstract 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
125000004432 carbon atom Chemical group C* 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
125000001475 halogen functional group Chemical group 0.000 abstract 1
125000000623 heterocyclic group Chemical group 0.000 abstract 1
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
208000008742 seborrheic dermatitis Diseases 0.000 abstract 1
125000001424 substituent group Chemical group 0.000 abstract 1
229940095585 testosterone-5-alpha reductase inhibitors for benign prostatic hypertrophy Drugs 0.000 abstract 1
125000001544 thienyl group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
- C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
- C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
- C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
- C07C2603/16—Benz[e]indenes; Hydrogenated benz[e]indenes

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)

AT87309949T 1986-11-20 1987-11-11 Topisches arzneimittel enthaltend 17-beta-methoxy-carbonyl-4-methyl-4-aza-5-alpha androst-1-en-3- one. ATE78827T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US93254986A	1986-11-20	1986-11-20
EP87309949A EP0271219B1 (de)	1986-11-20	1987-11-11	Topisches Arzneimittel enthaltend 17-beta-Methoxy-carbonyl-4-methyl-4-aza-5-alpha-androst-1-en-3-one

Publications (1)

Publication Number	Publication Date
ATE78827T1 true ATE78827T1 (de)	1992-08-15

Family

ID=25462482

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT87309949T ATE78827T1 (de)	1986-11-20	1987-11-11	Topisches arzneimittel enthaltend 17-beta-methoxy-carbonyl-4-methyl-4-aza-5-alpha androst-1-en-3- one.

Country Status (5)

Country	Link
EP (1)	EP0271219B1 (de)
JP (1)	JPS63139196A (de)
AT (1)	ATE78827T1 (de)
DE (1)	DE3780778T2 (de)
DK (1)	DK164915C (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5237061A (en) *	1988-10-31	1993-08-17	Merck & Co., Inc.	Methods of synthesizing benign prostatic hypertropic agents and their intermediates
US5061802A (en) *	1990-06-20	1991-10-29	Merck & Co. Inc.	17β-aminobenzoyl-4-aza-5α-androst-1-en-3-ones as benign prostatic hypertrophy agents
EP0462664A3 (en) *	1990-06-20	1992-11-25	Merck & Co. Inc.	Specific 17beta-thiobenzoyl-4-aza-5alpha-androst-1-en-3-ones as antiandrogenic agents
US5098908A (en) *	1990-06-20	1992-03-24	Merck & Co., Inc.	17β-hydroxybenzoyl-4-aza-5α-androst-1-en-3-ones as testosterone reductase inhibitors
US5151430A (en) *	1990-06-20	1992-09-29	Merck & Co., Inc.	Specific 17β-thiobenzoyl-4-aza-5α-androst-1-en-3-ones as antiandrogen agents
EP0462665A3 (en) *	1990-06-20	1993-06-30	Merck & Co. Inc.	Selected 17beta-polyaroyl-4-aza-5alpha-androst-1-en-3-ones as steroidal reductase inhibitors
US5061803A (en) *	1990-09-24	1991-10-29	Merck & Co., Inc.	Process for making 17-beta alkanoyl 3-oxo-4-aza-5-α-androst-1-enes
US5304562A (en) *	1991-10-09	1994-04-19	Ciba-Geigy Corporation	17β-substituted Aza-androstane derivatives
US5543406A (en) *	1991-12-20	1996-08-06	Glaxo Wellcome, Inc.	Inhibitors of 5-α-testosterone reductase
HUT71514A (en) *	1992-05-21	1995-12-28	Endorecherche Inc	Inhibitors of testosterone 5 alfa-reductase activity and pharmaceutical compositions containing the same
US5302589A (en) *	1992-08-07	1994-04-12	Glaxo, Inc.	Heterocyclic inhibitors of 5-α-testosterone reductase
TW369521B (en) *	1993-09-17	1999-09-11	Smithkline Beecham Corp	Androstenone derivative
TW408127B (en) *	1993-09-17	2000-10-11	Glaxo Inc	Androstenones
US5817818A (en) *	1994-09-16	1998-10-06	Glaxo Wellcome Inc.	Androstenones
US5541322A (en) *	1994-10-14	1996-07-30	Glaxo Wellcome Inc.	Synthesis of 6-azaandrostenones
US5656613A (en) *	1995-01-04	1997-08-12	Merck & Co., Inc.	Treatment of hyperandrogenic conditions
US5998427A (en) *	1998-05-14	1999-12-07	Glaxo Wellcome Inc.	Androstenones

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU527030B2 (en) *	1978-04-13	1983-02-10	Merck & Co., Inc.	4-aza-17-substituted-5a-androstan-3-ones
NZ211145A (en) *	1984-02-27	1988-10-28	Merck & Co Inc	4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions

1987
- 1987-11-11 AT AT87309949T patent/ATE78827T1/de not_active IP Right Cessation
- 1987-11-11 DE DE8787309949T patent/DE3780778T2/de not_active Expired - Fee Related
- 1987-11-11 EP EP87309949A patent/EP0271219B1/de not_active Expired - Lifetime
- 1987-11-19 DK DK607187A patent/DK164915C/da not_active IP Right Cessation
- 1987-11-20 JP JP62292214A patent/JPS63139196A/ja active Pending

Also Published As

Publication number	Publication date
EP0271219A1 (de)	1988-06-15
DE3780778D1 (de)	1992-09-03
DE3780778T2 (de)	1993-01-14
DK164915C (da)	1993-11-08
DK164915B (da)	1992-09-07
JPS63139196A (ja)	1988-06-10
EP0271219B1 (de)	1992-07-29
DK607187D0 (da)	1987-11-19
DK607187A (da)	1988-05-21

Similar Documents

Publication	Publication Date	Title
ATE78827T1 (de)	1992-08-15	Topisches arzneimittel enthaltend 17-beta-methoxy-carbonyl-4-methyl-4-aza-5-alpha androst-1-en-3- one.
DK165371C (da)	1993-04-05	17beta-n-monosubstituerede carbamoyl-4-aza-5alfa-androst-1-en-3-on-forbindelser og praeparater indeholdende disse forbindelser
IE922862L (en)	1985-08-27	17 Beta-Acyl-4-Aza-5 Alpha-androst-1-ene-3-ones as 5 alpha-reductase inhibitors
ATE67503T1 (de)	1991-10-15	17-beta-substituierte-4-aza-5-alpha-androstenon und ihre anwendung als 5-alpha-reduktaseinhibitoren.
RU94045915A (ru)	1996-09-10	Производные индола, способ их получения, фармкомпозиция
AU8816298A (en)	1999-03-16	Oxindolylquinazoline derivatives as angiogenesis inhibitors
NO174711C (no)	1994-06-22	Analogifremgangsmåte for fremstilling av nye, terapeutisk aktive pyrimidindionderivater
NO304070B1 (no)	1998-10-19	Benzimidazolon-derivater, farmasöytiske preparater inneholdende dem og anvendelse av dem
AU7517400A (en)	2001-04-24	N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
DK0567271T3 (da)	1998-02-16	Steroidderivater til behandling af prostatahypertrofi, fremgangsmåde til fremstilling heraf og anvendelser heraf
DE3785136D1 (de)	1993-05-06	Arzneimittel zur inhibition von hautfalte.
CA2102209A1 (en)	1992-11-02	Novel Isoxazole Derivative and Salt Thereof
PL309874A1 (en)	1996-02-05	Novel derivatives of pyrrolocarbasol, method of obtaining them and pharmaceutical composition containing such derivatives
NO984740L (no)	1998-10-09	Isatinderivater som acetylcholinesteraseinhibitorer og analgetiske midler
GB9708917D0 (en)	1997-06-25	Compounds useful in therapy
PT87277A (pt)	1988-05-01	Process for the preparation of new bicyclic compounds and pharmaceutical compositions comprising same
HU9800970D0 (en)	1998-06-29	Process for producing pharmaceutical compositions containing heptapeptide somatostatin derivatives of neurogene- and non-neurogene-antiflogistic and analgesic activity and peptidomimetica
DE68926810D1 (de)	1996-08-14	Benzoxazepinon-Verfahren
DE3688960D1 (de)	1993-10-07	Synthese von Beta-Lactamverbindungen.
DK1161424T3 (da)	2004-09-13	Hidtil ukendte diazolderivater som serotonerge midler
DK369289D0 (da)	1989-07-26	Anvendelse af imidazopyrazolderivater som analgetica og antiinflammatoriske midler
NO993608D0 (no)	1999-07-23	Nye 8H-tieno-[2,3-b]pyrrolizin-8-on forbindelser, fremgangsmåte ved deres fremstilling og farmasoeytiske sammensetninger inneholdende dem
SU1351052A1 (ru)	1997-10-20	Способ получения арил (омега -гидразино)алкилсульфидов
DE69314929D1 (de)	1997-12-04	Benzolderivate
DE3778088D1 (de)	1992-05-14	Substituierte pyrimidochinoxaline.

Legal Events

Date	Code	Title	Description
1993-01-15	UEP	Publication of translation of european patent specification
1994-08-15	REN	Ceased due to non-payment of the annual fee